December 4, 2025Journal of Clinical MedicineOpen Access

Chronic Hydroxyurea Therapy in Children with Sickle Cell Anemia: Mechanisms of Action, Systemic Effects, and Long-Term Safety

View Full Paper

Ask AI

Bookmark

Authors

MBMartina Berzieri GCGiulia Carbone DCDavide Ciriaco

Discussion

Member takes

Overview

Review highlights the long-term safety and mortality improvement with Hydroxyurea in children, suggesting neuroprotective benefits and monitoring for adverse events.

Key Points

Chronic Hydroxyurea therapy significantly reduces mortality in children with sickle cell disease, improving overall life quality.
Analysis revealed lowered leukocyte counts, reduced acute chest syndrome, and enhanced red blood cell deformability with treatment.
Literature review across multiple studies demonstrated benefits in neuroprotective effects and modulation of inflammatory pathways.
Long-term Hydroxyurea usage shows no malignancy risk, with adverse events primarily being dose-dependent and manageable.

Cite This Study

Berzieri et al. (2025) studied this question.

synapsesocial.com/papers/694023fa2d562116f28fdc3a https://doi.org/10.3390/jcm14238599

View Full Paper

Ask AI

Bookmark

December 4, 2025Journal of Clinical MedicineOpen Access

Chronic Hydroxyurea Therapy in Children with Sickle Cell Anemia: Mechanisms of Action, Systemic Effects, and Long-Term Safety

View Full Paper

Ask AI

Bookmark

Authors

MBMartina Berzieri GCGiulia Carbone DCDavide Ciriaco

Discussion

Member takes

Overview

Review highlights the long-term safety and mortality improvement with Hydroxyurea in children, suggesting neuroprotective benefits and monitoring for adverse events.

Key Points

Chronic Hydroxyurea therapy significantly reduces mortality in children with sickle cell disease, improving overall life quality.
Analysis revealed lowered leukocyte counts, reduced acute chest syndrome, and enhanced red blood cell deformability with treatment.
Literature review across multiple studies demonstrated benefits in neuroprotective effects and modulation of inflammatory pathways.
Long-term Hydroxyurea usage shows no malignancy risk, with adverse events primarily being dose-dependent and manageable.

Cite This Study

Berzieri et al. (2025) studied this question.

synapsesocial.com/papers/694023fa2d562116f28fdc3a https://doi.org/10.3390/jcm14238599

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark